CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

類似資料

• An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy
  著者:: Xin Li, 等
  出版事項: (2025-06-01)
• Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
  著者:: Chen, Cong, 等
  出版事項: (2021)
• Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
  著者:: Perna, Fabiana, 等
  出版事項: (2016)
• CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL
  出版事項: (2020)
• CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy
  著者:: Thapa, Bicky, 等
  出版事項: (2020)